Patents Represented by Attorney Incyte Pharmaceuticals
  • Patent number: 5985638
    Abstract: The present invention provides a human microsomal signal peptidase subunit (HMSP) and polynucleotides which encode HMSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HMSP.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5985635
    Abstract: The present invention provides human serine/threonine kinase (HSTK) and polynucleotides which identify and encode HSTK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSTK and a method for producing HSTK. The invention also provides for use of HSTK and agonists, antibodies, or antagonists specifically binding HSTK, in the prevention and treatment of diseases associated with expression of HSTK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSTK for the treatment of diseases associated with the expression of HSTK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSTK.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5986057
    Abstract: The present invention provides a human vesicle trafficking protein (HVTP) and polynucleotides which identify and encode HVTP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HVTP and for treating or preventing disorders associated with expression of HVTP.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley
  • Patent number: 5985604
    Abstract: The present invention provides a human sodium-dependent phosphate cotransporter (NAPTR) and polynucleotides which identify and encode NAPTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NAPTR and a method for producing NAPTR. The invention also provides for agonists, antibodies, or antagonists specifically for NAPTR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NAPTR for the treatment of diseases associated with the expression of NAPTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NAPTR. The invention also provides a method for treating disorders associated with decreased phosphate levels by administering NAPTR and a method for treating disorders associated with increased phosphate levels by administering antagonists to NAPTR.
    Type: Grant
    Filed: February 24, 1997
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Olga Bandman
  • Patent number: 5981226
    Abstract: The invention provides human vesicle transport associated proteins (VTAP) and polynucleotides which identify and encode VTAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of VTAP.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: November 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Purvi Shah, Neil C. Corley
  • Patent number: 5981242
    Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.
    Type: Grant
    Filed: February 3, 1999
    Date of Patent: November 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
  • Patent number: 5981263
    Abstract: The invention provides a human matrilin-3 (MAT-3) and polynucleotides which identify and encode MAT-3. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MAT-3.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: November 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah, Matthew Kaser
  • Patent number: 5981232
    Abstract: The present invention provides a human pyrophosphatase (HPYP) and polynucleotides which identify and encode HPYP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPYP and a method for producing HPYP. The invention also provides for use of HPYP and agonists, antibodies, or antagonists specifically binding HPYP, in the prevention and treatment of cancer and inflammatory diseases. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPYP for the treatment of diseases associated with the expression of HPYP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPYP.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: November 9, 1999
    Assignee: Inctye Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5981244
    Abstract: The invention provides a human aflatoxin B1 aldehyde reductase (AFB1-hAR) and polynucleotides which identify and encode AFB1-hAR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of AFB1-hAR.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: November 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Purvi Shah, Karl J. Guegler, Neil C. Corley
  • Patent number: 5981192
    Abstract: The invention provides a human vesicle transport protein (NVTP-1) and polynucleotides which identify and encode NVTP-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NVTP-1.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: November 9, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Neil C. Corley, Preeti Lal
  • Patent number: 5977072
    Abstract: The invention provides a human high affinity immunoglobulin E receptor-like protein (IGERB) and polynucleotides which identify and encode IGERB. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IGERB.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
  • Patent number: 5976528
    Abstract: The present invention provides a human glutathione S-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5976801
    Abstract: The invention provides two human reticulocalbin isoforms designated individually as RCN .gamma. and RCN .delta. and collectively as RCN, and polynucleotides which identify and encode RCN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of RCN.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharamceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
  • Patent number: 5977320
    Abstract: The present invention provides a novel human phosphorylase kinase gamma subunit (HPHKG) and the polynucleotide which identifies and encodes HPHKG. The invention provides for expression vectors and host cells comprising the nucleic acid sequence encoding HPHKG. The invention also provides pharmaceutical compositions containing purified HPHKG or antisense molecules to HPHKG for the treatment of diseases associated with expression of HPHKG. The invention also includes diagnostic compositions containing the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding HPHKG or anti-HPHKG antibodies which specifically bind to HPHKG, and the use of such compositions for diagnosis of disease.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli
  • Patent number: 5977338
    Abstract: The present invention provides a novel human interferon-inducible protein (HIFI) and the polynucleotides which identify and encode HIFI. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HIFI and for a method for producing the protein. The invention also provides pharmaceutical compositions containing HIFI and the use of such compositions for the prevention or treatment of diseases associated with the expression of HIFI. Additionally, the invention provides antisense molecules to HIFI and their use in the treatment of diseases associated with the expression of HIFI. The invention also provides diagnostic assays which utilize polynucleotides which hybridize with naturally occurring sequences encoding HIFI and antibodies which specifically bind to the protein.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Phillip R. Hawkins
  • Patent number: 5976804
    Abstract: The invention provides a human NADH dehydrogenase subunit (HND-1) and polynucleotides which identify and encode HND-1. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HND-1.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Karl J. Guegler
  • Patent number: 5976865
    Abstract: The invention provides a human vesicle transport related protein (VTRP) and polynucleotides which identify and encode VTRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of VTRP.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Neil C. Corley, Purvi Shah
  • Patent number: 5972684
    Abstract: The invention provides a human carbonic anhydrase isoform (CAVIII) and polynucleotides which identify and encode CAVIII. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of CAVIII.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: October 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Henry Yue, Sara R. Greenwald, Neil C. Corley
  • Patent number: 5972653
    Abstract: The invention provides a human protein of embryogenesis (PREM) and polynucleotides which identify and encode PREM. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PREM.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: October 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley
  • Patent number: 5973130
    Abstract: The present invention provides a human Ras-like protein (RLP) and polynucleotides which identify and encode RLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing RLP and for treating or preventing disorders associated with expression of RLP.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: October 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli, Neil C. Corley